Randy Sabett

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million

Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.

Cooley advised the underwriters of Shoulder Innovations, a medical technology company exclusively focused on transforming the shoulder surgical care market, in connection with Shoulder Innovations’ $75 million initial public offering (IPO).

Cooley advised Blue Owl (NYSE: OWL), a leading asset manager redefining alternatives, on an up to $500 million term loan facility for Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis.

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.